Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Pharming announces public cash offer to the shareholders of Abliva AB Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product...
Pharming announces positive topline data in pediatric clinical trial of leniolisib Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare...
Pharming Group reports third quarter 2024 financial results and provides business update Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023...
Pharming Group to report third quarter 2024 financial results on October 24 Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR...
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation Proof of concept clinical trial will evaluate leniolisib in...
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated...
Pharming Group reports second quarter and first half 2024 financial results and provides business update Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the...
Pharming Group to report second quarter and first half 2024 financial results on August 1 Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam:...
Pharming Group to participate in June investor conferences Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that...
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union Leiden, the Netherlands, May 30, 2024: Pharming Group N.V...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.087 | 10.1754385965 | 0.855 | 0.9485 | 0.846 | 106953 | 0.88982446 | DE |
| 4 | 0.2105 | 28.7764866712 | 0.7315 | 0.95 | 0.696 | 81925 | 0.83118974 | DE |
| 12 | 0.2095 | 28.6006825939 | 0.7325 | 0.95 | 0.6895 | 54221 | 0.79527347 | DE |
| 26 | 0.182 | 23.9473684211 | 0.76 | 0.9505 | 0.639 | 50669 | 0.7711069 | DE |
| 52 | -0.131 | -12.2087604846 | 1.073 | 1.22 | 0.639 | 57475 | 0.92180038 | DE |
| 156 | -0.236 | -20.0339558574 | 1.178 | 1.311 | 0.639 | 50346 | 0.94721756 | DE |
| 260 | -0.236 | -20.0339558574 | 1.178 | 1.311 | 0.639 | 50346 | 0.94721756 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
